Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Epigenetic Regulation in Hematologic Malignancies
share announcement

Epigenetic Regulation in Hematologic Malignancies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 3201

Special Issue Editor

Dr. Travis S. Johnson

E-Mail Website
Guest Editor
Indiana University School of Medicine, Indianapolis, IN, USA
Interests: omnics

Special Issue Information

Dear Colleagues,

We are pleased to announce the call for submissions to a Special Issue of Cancers focused on the topic of "Epigenetic Regulation in Hematologic Malignancies." Epigenetic mechanisms play a critical role in the development, progression, and treatment response of hematologic malignancies. DNA methylation, histone modifications, and non-coding RNA regulation have emerged as key regulators in this context. Understanding the epigenetic regulation in hematologic malignancies holds significant potential for the development of novel therapeutic approaches and improved patient outcomes.

This Special Issue aims to provide a comprehensive overview of current research and advancements in the field of epigenetic regulation in hematologic malignancies. We invite the submission of original research articles and reviews covering various aspects of this topic, including but not limited to:

  • 1. Epigenetic alterations in hematologic malignancies;
  • 2. Interplay between malignant cells and the tumor microenvironment mediated by epigenetic modifications;
  • 3. The role of non-coding RNAs in modulating the tumor microenvironment in hematologic malignancies;
  • 4. Epigenetic regulation of immune responses in hematologic malignancies;
  • 5. Therapeutic targeting of epigenetic regulators in hematologic malignancies.

All submitted articles will undergo a rigorous peer review process to ensure the highest scientific quality and relevance to the field. We encourage contributions from researchers, clinicians, and experts in the field of hematologic malignancies and epigenetics.

By consolidating the latest research findings and clinical experiences, we aim to deepen our understanding of the intricate interplay between epigenetic alterations and hematologic malignancies. Furthermore, we anticipate that this Special Issue will facilitate the development of innovative therapeutic strategies targeting the epigenetic regulation in hematologic malignancies.

If you have any questions, require further information, or need any assistance, please do not hesitate to reach out to us. Our team is dedicated to supporting and facilitating your participation in this Special Issue.

Thank you for your attention to this matter, and we eagerly await your valuable submissions.

Dr. Travis S. Johnson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epigenetic regulation
  • hematologic malignancies
  • DNA methylation
  • non-coding RNA
  • therapeutic targeting

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

14 pages, 1803 KiB  
Review
A Room for Long-Lived Plasma Cell Contribution in Immune Cytopenias?
by Tricia Don, Manisha Gadgeel and Süreyya Savaşan
Cancers 2025, 17(9), 1537; https://doi.org/10.3390/cancers17091537 - 1 May 2025
Viewed by 188
Abstract
Immune cytopenias, such as autoimmune hemolytic anemia, immune thrombocytopenia, and Evans syndrome, are characterized by autoantibodies targeting various blood cells, initiating their destruction. Interactions between T cells, B cells, their ultimate maturational plasma cell descendants, dendritic cells, and macrophages result in antibody production, [...] Read more.
Immune cytopenias, such as autoimmune hemolytic anemia, immune thrombocytopenia, and Evans syndrome, are characterized by autoantibodies targeting various blood cells, initiating their destruction. Interactions between T cells, B cells, their ultimate maturational plasma cell descendants, dendritic cells, and macrophages result in antibody production, including the autoreactive ones. Autoimmune phenomena can be idiopathic or associated with various immune dysregulation conditions or malignancies. Interventions disrupting this complex network at different levels have been used to treat immune cytopenias with certain levels of success. Some cases are known to be refractory to many different therapeutic approaches, including the ones eliminating B cells. In some such cases, targeting plasma cells resulted in disease control. Among plasma cell compartments, unique long-lived plasma cells (LLPCs) residing primarily in the bone marrow, are specialized antibody-producing cells with an extended lifespan, capable of persistently secreting antibodies. LLPCs can evade conventional therapeutic strategies designed to target often-proliferating cells. Research focusing on the role of LLPCs in autoimmune phenomena including immune cytopenias has provided evidence for their role, characterized by the sustained production of autoantibodies. Frequent genetic mutations and progression to other immune dysregulation entities have been reported in a group of children with immune cytopenias. This might provide new insights focusing on the potential underlying genetic and epigenetic mechanisms leading to generation and maintenance of LLPCs in autoimmune disorders. We provide a brief review of LLPC biology and evidence for their role in immune cytopenias with potential future implications in this article. Full article
(This article belongs to the Special Issue Epigenetic Regulation in Hematologic Malignancies)
►▼ Show Figures

Figure 1

23 pages, 4036 KiB  
Review
Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical Implications
by Sihong Li, Jiahui Liu, Madeline Peyton, Olivia Lazaro, Sean D. McCabe, Xiaoqing Huang, Yunlong Liu, Zanyu Shi, Zhiqi Zhang, Brian A. Walker and Travis S. Johnson
Cancers 2025, 17(4), 653; https://doi.org/10.3390/cancers17040653 - 14 Feb 2025
Viewed by 1268
Abstract
Multiple myeloma (MM) is a complex and heterogeneous hematologic malignancy characterized by clonal evolution, genetic instability, and interactions with a supportive tumor microenvironment. These factors contribute to treatment resistance, disease progression, and significant variability in clinical outcomes among patients. This review explores the [...] Read more.
Multiple myeloma (MM) is a complex and heterogeneous hematologic malignancy characterized by clonal evolution, genetic instability, and interactions with a supportive tumor microenvironment. These factors contribute to treatment resistance, disease progression, and significant variability in clinical outcomes among patients. This review explores the mechanisms underlying MM progression, including the genetic and epigenetic changes that drive clonal evolution, the role of the bone marrow microenvironment in supporting tumor growth and immune evasion, and the impact of genomic instability. We highlight the critical insights gained from single-cell technologies, such as single-cell transcriptomics, genomics, and multiomics, which have enabled a detailed understanding of MM heterogeneity at the cellular level, facilitating the identification of rare cell populations and mechanisms of drug resistance. Despite the promise of advanced technologies, MM remains an incurable disease and challenges remain in their clinical application, including high costs, data complexity, and the need for standardized bioinformatics and ethical considerations. This review emphasizes the importance of continued research and collaboration to address these challenges, ultimately aiming to enhance personalized treatment strategies and improve patient outcomes in MM. Full article
(This article belongs to the Special Issue Epigenetic Regulation in Hematologic Malignancies)
►▼ Show Figures

Figure 1

Other

Jump to: Review

23 pages, 1359 KiB  
Systematic Review
Potential Use of Exosomal Non-Coding MicroRNAs in Leukemia Therapy: A Systematic Review
by Paulina Gil-Kulik, Natalia Kluz, Dominika Przywara, Alicja Petniak, Małgorzata Wasilewska, Natalia Frączek-Chudzik and Marek Cieśla
Cancers 2024, 16(23), 3948; https://doi.org/10.3390/cancers16233948 - 25 Nov 2024
Cited by 1 | Viewed by 1149
Abstract
Leukemia is a heterogeneous group of hematological malignancies. Despite the enormous progress that has been made in the field of hemato-oncology in recent years, there are still many problems related to, among others, disease recurrence and drug resistance, which is why the search [...] Read more.
Leukemia is a heterogeneous group of hematological malignancies. Despite the enormous progress that has been made in the field of hemato-oncology in recent years, there are still many problems related to, among others, disease recurrence and drug resistance, which is why the search for ideal biomarkers with high clinical utility continues. Research shows that exosomes play a critical role in the biology of leukemia and are associated with the drug resistance, metastasis, and immune status of leukemias. Exosomes with their cargo of non-coding RNAs act as a kind of intermediary in intercellular communication and, at the same time, have the ability to manipulate the cell microenvironment and influence the reaction, proliferative, angiogenic, and migratory properties of cells. Exosomal ncRNAs (in particular, circRNAs and microRNAs) appear to be promising cell-free biomarkers for diagnostic, prognostic, and treatment monitoring of leukemias. This review examines the expression of exosomal ncRNAs in leukemias and their potential regulatory role in leukemia therapy but also in conditions such as disease relapse, drug resistance, metastasis, and immune status. Given the key role of ncRNAs in regulating gene networks and intracellular pathways through their ability to interact with DNA, transcripts, and proteins and identifying their specific target genes, defining potential functions and therapeutic strategies will provide valuable information. Full article
(This article belongs to the Special Issue Epigenetic Regulation in Hematologic Malignancies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop